Among diverse cancers (N = 102,878), high TMB status was significantly less frequent in patients with MDM2 amplification than in the MDM2 wild-type population (2.9% [105 of 3,650] v 6.5% [6,492 of 99,228], respectively; P < .001). This evidence concerns the gene MDM2 and cancer.